Holen Sie sich die Stockscreener-App
10.54
1.54%
0.16
Schlusskurs vom Vortag:
$10.38
Offen:
$10.32
24-Stunden-Volumen:
5,847
Relative Volume:
0.18
Marktkapitalisierung:
$94.52M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.62M
KGV:
-0.5431
EPS:
-19.4076
Netto-Cashflow:
$-35.63M
1W Leistung:
-1.50%
1M Leistung:
+1.01%
6M Leistung:
+25.18%
1J Leistung:
-15.68%
1-Tages-Spanne:
$10.32
$10.75
1-Wochen-Bereich:
$10.00
$10.87
52-Wochen-Spanne:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
10.54 | 94.52M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
ProMIS Neurosciences Inc (PMN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ProMIS Neurosciences Inc (PMN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ProMIS Neurosciences Inc (PMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProMIS Neurosciences Inc (PMN) Valuation: PE, PB & Fair Value Analysis - TradingKey
ProMIS Neurosciences Inc (PMN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProMIS Neurosciences Inc (PMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProMIS Neurosciences Inc (PMN) Institutional Confidence - TradingKey
PMN Q1 2026 Earnings: EPS Beat Surprises as ProMIS Advances PipelinePretax Income Report - newsline.com
PMN Q1 2026 Earnings: Narrowing Losses Amidst Clinical ProgressProfit Inflection Point - newsline.com
ProMIS Neurosciences (PMN) Dips 3.54% as Biotech Stock Tests Key Support ZonePrice Action Signals - newsline.com
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy - Yahoo Finance
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet - Yahoo Finance
ProMIS Neurosciences Inc. (PMN) Q1 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pipeline AdvancesAnalyst Drop Coverage - newsline.com
H.C. Wainwright reiterates Buy on ProMIS Neurosciences stock By Investing.com - Investing.com Canada
PMN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
H.C. Wainwright Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $18 - Moomoo
PMN Q1 2026 Earnings: Narrower-than-Expected Loss Amid Ongoing Clinical DevelopmentROA Comparison - newsline.com
ProMIS Neurosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
PMN Q1 2026 Earnings: EPS Surprises to the Upside Despite Lack of RevenueMargin Guidance - newsline.com
ProMIS Neurosciences (PMN) Slips 3.3% as Biotech Sentiment Shifts – Key Support Holds at $9.56Median Line - newsline.com
ProMIS Neurosciences (PMN) Faces Bearish Pressure as Shares Slide 3.70%Value Stock Ideas - newsline.com
ProMIS Neurosciences (PMN) Holds Steady Near Support as Biotech Sector Watches Key LevelsSynthetic Short - newsline.com
ProMIS Neurosciences to Participate in Upcoming Conferences in June - The Manila Times
Alzheimer’s drug trial data from ProMIS expected in early Q3 2026 - Stock Titan
PMN Technical Analysis | Trend, Signals & Chart Patterns | PROMIS NEUROSCIENCES INC (NASDAQ:PMN) - ChartMill
ProMIS Neurosciences (PMN) Slips 5.65% as Shares Test Key Support LevelWave Alternation - newsline.com
PMN Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Progress in Neurodegenerative PipelineRevenue Breakdown Analysis - The Legal Advocate
PMN Q1 2026 Earnings: Narrower-than-expected Loss; Stock Gains on Pipeline ProgressPretax Income Report - Newser
Yu Fan's ProMIS Neurosciences Inc(PMN) Holding History - GuruFocus
ProMIS Neurosciences (PMN) director granted 16,500 options at $10.77 strike price - Stock Titan
ProMIS Neurosciences (PMN) director granted options on 16,500 shares - Stock Titan
ProMIS Neurosciences (PMN) CEO awarded 160,000 options at $10.77 strike - Stock Titan
ProMIS Neurosciences (PMN) director awarded long-dated stock options - Stock Titan
ProMIS Neurosciences (PMN) awards CSO 50,000 options vesting over 4 years - Stock Titan
Executive at ProMIS (PMN) receives 18,167 stock options expiring 2036 - Stock Titan
ProMIS Neurosciences (PMN) director receives 16,500 stock options grant - Stock Titan
ProMIS Neurosciences (PMN) CDO awarded 50,000 stock options - Stock Titan
Director at ProMIS Neurosciences (PMN) receives new option grants as board compensation - Stock Titan
PMN Q1 2026 Earnings: Narrowed EPS Surprise Drives Positive Stock ReactionDividend Earnings Report - The Legal Advocate
ProMIS Neurosciences (NASDAQ: PMN) shareholders approve larger 2025 stock option plan - Stock Titan
Analysts’ Top Healthcare Picks: ProMIS Neurosciences (PMN), Evolent Health (EVH) - The Globe and Mail
Great Point, Dr. Jay and Nordahl report 9.99% stake in PROMIS (PMN) - Stock Titan
Wellington Group discloses 895,871-share holding in ProMIS (PMN) - Stock Titan
ProMIS Neurosciences Inc. Q1 2026 Financial Results, Forward-Looking Statements, and Risk Factors Overview - Minichart
TradingKey - TradingKey
ProMIS Neurosciences Releases Q1 2026 Financial Results - AlphaStreet
ProMIS Neurosciences Reports Q1 2026 Results, Advances Alzheimer’s PMN310 Trial and Secures $175M Financing - Minichart
ProMIS Neurosciences (PMN) Q1 2026 Earnings: EPS N/A, Revenue N/ - GuruFocus
ProMIS (PMN) Targets Alzheimer's Treatment with Promising Trial and Funding - GuruFocus
ProMIS Neurosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
ProMIS Neurosciences Inc. Q1 2026: Net income $(8.24M), Diluted EPS $(1.26) — 10-Q Summary - TradingView
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):